Sat Sep 14 07:36:00 UTC 2024: ## French Court Orders Sanofi to Pay €280,000 to Mother of Children Harmed by Anti-Epileptic Drug
**Paris, France** – A French court has ordered pharmaceutical giant Sanofi to pay €280,000 (£236,539) to a mother whose children suffered birth defects and developmental problems after she was prescribed the anti-epileptic drug Dépakine (known as Epilim in the UK) during her pregnancies.
The ruling, which could pave the way for hundreds of similar lawsuits, comes after years of campaigning by victims and their families, who allege that Sanofi failed to adequately warn about the risks associated with the drug. The court found Sanofi liable for failing to provide sufficient information on the risks of malformation and neurodevelopmental problems, continuing to market a product it knew to be defective, and neglecting to exercise due diligence during the mother’s pregnancies.
The case was brought by Marine Martin, whose eldest daughter Salomé was born with facial malformations and suffers from dyspraxia, while her youngest son Florent was born with malformations requiring surgery and diagnosed with Asperger’s autism.
“This judgment sends a clear message that Sanofi could and should have acted in a way to prevent harm,” said Emma Friedmann, a British campaigner whose son Andy was affected by valproate. She criticized the UK’s legal system for failing to provide adequate avenues for victims to seek compensation.
The case has reignited calls for a government-funded redress scheme in the UK, where a similar legal challenge against Sanofi was discontinued in 2010 after funding was terminated. The Cumberlege review, which investigated valproate alongside other drugs, concluded that avoidable harm had been caused to patients and recommended a government-backed compensation fund.
While France established a National Office for Compensation for Medical Accidents in 2017, which has already paid out nearly €58m to 1,120 valproate victims, the UK government has yet to introduce a similar program.
Sanofi has stated that it intends to appeal the French court’s decision, arguing that it complied with its legal obligations by informing the French Health Authority of the risks and requesting changes to its information documents as scientific knowledge evolved.
The company also claims that the Health Authority, not Sanofi, is responsible for communicating information about medicinal products to patients, and that it was healthcare professionals who should have informed patients about the risks.
The case highlights a broader issue of pharmaceutical company responsibility in communicating potential risks associated with their products, and the need for effective regulatory oversight and compensation mechanisms for those who suffer harm.
First Piper 